Anifrolumab (Saphnelo) Gets Green Light for Approval in EU

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for anifrolumab (Saphnelo) as an add-on treatment for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy, according to an announcement on Dec. 16.

Anifrolumab, a monoclonal antibody that binds to subunit 1 of the type I interferon receptor and thereby blocks the biologic activity of type I interferons, was approved by the US Food and Drug Administration in July 2021.

The recommendation for anifrolumab is based on its ability to elicit a clinical response on the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at week 52, which is defined as improvement in all organ domains with moderate or severe SLE activity at baseline.

The manufacturer AstraZeneca said the biologic drug will be available as a 300 mg concentrate for solution for infusion.

The most common adverse reactions are upper respiratory tract infection, bronchitis, infusion-related reaction, and herpes zoster. The most common serious adverse reaction was herpes zoster.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
VIDEO thumbnail

VIDEO

Immer mehr Venezianer fürchten den Untergang ihrer Heimat. Scheibchenweise wird die Stadt an Touristen und Investoren verkauft. Viele Venezianer flüchten aufs Festland. Doch nicht alle wollen diesem Untergang tatenlos zuschauen – denn ein Venedig ohne Venezianer würde seine Seele verlieren. NZZ Format reist nach Venedig und besucht jene, die ihre Stadt lieben und retten wollen.…
Read More
New Hope Against Painful Skin Issues Caused by Radiation Therapy thumbnail

New Hope Against Painful Skin Issues Caused by Radiation Therapy

Please enable cookies. Error 1005 Ray ID: 7d87bde2ada631d5 • 2023-06-17 02:07:55 UTC What happened? The owner of this website (www.webmd.com) has banned the autonomous system number (ASN) your IP address is in (47583) from accessing this website. Was this page helpful? Thank you for your feedback! Cloudflare Ray ID: 7d87bde2ada631d5 • Your IP: 89.117.245.16 •
Read More
Are Cortisone Injections Good or Bad for Arthritic Knees? thumbnail

Are Cortisone Injections Good or Bad for Arthritic Knees?

By Dennis Thompson HealthDay ReporterTUESDAY, Dec. 21, 2021 (HealthDay News) -- Cortisone injections have gotten a bad rap in recent years as a treatment for arthritis pain, because steroids are known to damage cartilage and could potentially cause the joint to further deteriorate.But a new study suggests that if used wisely, cortisone shots are as…
Read More
High Rate of Negative Cancer Trials Raises Concerns thumbnail

High Rate of Negative Cancer Trials Raises Concerns

More than 80% of recent phase III trials in cancer conducted over a 10-year period failed to show clinically meaningful improvement in overall survival (OS), according to a review of the data. Among 187 trials with a primary endpoint of OS, 131 did not achieve statistically significant improvement. Of the 56 studies that met statistical…
Read More
Telehealth revenue could hit $20B in five years, say analysts thumbnail

Telehealth revenue could hit $20B in five years, say analysts

A new report released this week from Bloomberg Intelligence predicted that the telehealth sector could bring in $20 billion in U.S. revenue by 2027.   The Digital Reshaping the Health Care Ecosystem publication said that virtual care is set to "become a staple" of healthcare delivery. "The COVID-19 pandemic has accelerated the adoption of telehealth…
Read More
Index Of News
Total
0
Share